Number of pages: 100 | Report Format: PDF | Published date: February 27, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
Report Attribute |
Details |
Market Size Value in 2021 |
US$ 97.12 million |
Revenue Forecast in 2030 |
US$ 216.21 million |
CAGR |
9.3% |
Base Year for Estimation |
2021 |
Forecast Period |
2022-2030 |
Historical Year |
2020 |
Segments Covered |
Drug Class, Distribution Channel, and Region |
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global endogenous Cushing’s syndrome therapeutics market was valued at US$ 97.12 million in 2021 and is expected to register a revenue CAGR of 9.3% to reach US$ 216.21 million by 2030.
Endogenous Cushing’s Syndrome Therapeutics Market Fundamentals
Endogenous Cushing’s syndrome is a medical condition caused by the overproduction of cortisol hormone by the adrenal glands. Cortisol is a hormone that regulates various bodily functions, including blood pressure, immune response, and metabolism. Endogenous Cushing’s syndrome can result from various causes, including a tumor in the pituitary gland or adrenal gland or from an overproduction of adrenocorticotropic hormone (ACTH) by the pituitary gland. Symptoms of endogenous Cushing’s syndrome include weight gain, muscle weakness, thinning of the skin, high blood pressure, high blood sugar levels, mood changes, and decreased libido. Treatment depends on the underlying cause and may include surgery, medication, or radiation therapy. The goal of treatment is to reduce cortisol levels in the body and alleviate the symptoms of the syndrome.
The market for endogenous Cushing’s syndrome therapeutics is expected to grow in the coming years, due to increased awareness and diagnosis of the condition. However, the high cost of treatment, the limited availability of drugs, and the rarity of the disease are some of the challenges that could affect the growth of the market. Despite the challenges, there is ongoing research to develop new treatments for endogenous Cushing’s syndrome, including novel therapies that target specific mechanisms involved in cortisol production. New drugs that specifically target the underlying causes of the condition, such as inhibitors of cortisol synthesis or signaling, are currently in development.
Overall, the endogenous Cushing’s syndrome therapeutics market is expected to register modest revenue growth in the coming years, driven by advancements in research and development, increased awareness, and improvements in diagnosis and treatment.
[768686]
Endogenous Cushing’s Syndrome Therapeutics Market Dynamics
The prevalence of endogenous Cushing’s syndrome is increasing globally due to the rise in risk factors, such as obesity, diabetes, and hypertension. This is driving the growth of the endogenous Cushing’s syndrome therapeutics market. According to the National Center for Biotechnology Information, endogenous Cushing’s syndrome accounts for 60-80% of all cases of Cushing’s syndrome globally. The increasing awareness about Cushing’s syndrome among healthcare professionals and patients is leading to early diagnosis and treatment, which is propelling revenue growth in the endogenous Cushing’s syndrome therapeutics market. Technological advancements in diagnostic tools, such as cortisol assays, imaging techniques, and genetic testing, are leading to more accurate and timely diagnoses of Cushing’s syndrome, which is driving the demand for endogenous Cushing’s syndrome therapeutics.
The growing focus on developing targeted therapies that address the specific underlying cause of endogenous Cushing’s syndrome, such as cortisol synthesis inhibitors, pituitary-directed therapies, and immunomodulatory drugs, is boosting revenue growth in the endogenous Cushing’s syndrome therapeutics market. Governments in various countries are providing funding and support for research and development activities related to Cushing’s syndrome. This is driving innovation and the introduction of new therapies, which is fueling the development of the endogenous Cushing’s syndrome therapeutics market.
However, the high cost related to endogenous Cushing’s syndrome therapeutics is restricting the global market. Endogenous Cushing’s syndrome is a rare disorder, and the patient population is limited, which is also hindering revenue growth of the endogenous Cushing’s syndrome therapeutics market.
Endogenous Cushing’s Syndrome Therapeutics Market Ecosystem
The global endogenous Cushing’s syndrome therapeutics market is analyzed from three perspectives: drug class, distribution channel, and region.
Endogenous Cushing’s Syndrome Therapeutics Market by Drug Class
[8676575]
Based on the drug class, the global endogenous Cushing’s syndrome therapeutics market is segmented into 11-beta-hydroxylase inhibitors, somatostatin analogs, adrenal steroid inhibitors, glucocorticoid receptor antagonists, and adrenolytic agents.
The adrenal steroid inhibitors segment dominated the endogenous Cushing’s syndrome therapeutics market with the largest revenue share in 2021. Adrenal steroid inhibitors are currently the most commonly used drug class for the medical management of endogenous Cushing’s syndrome. They are effective in reducing cortisol levels in patients with endogenous Cushing’s syndrome. Compared to other drugs used to treat endogenous Cushing’s syndrome, adrenal steroid inhibitors are relatively affordable. This has contributed to its widespread usage as a first-line treatment option, which is boosting segmental growth. Adrenal steroid inhibitors are widely available and are approved for usage in many countries. This makes adrenal steroid inhibitors easily accessible for patients with endogenous Cushing’s syndrome. Moreover, these inhibitors have a well-established safety profile and are generally well-tolerated by patients. This has also contributed to its popularity in the market. Despite the availability of other drugs to treat endogenous Cushing’s syndrome, adrenal steroid inhibitors remain the most widely used medication for medical management due to the absence of alternative treatments that offer similar levels of effectiveness, safety, and affordability as adrenal steroid inhibitors.
Endogenous Cushing’s Syndrome Therapeutics Market by Distribution Channel
Based on the distribution channel, the global endogenous Cushing’s syndrome therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
The hospital pharmacy segment accounted for a significant revenue share of the endogenous Cushing’s syndrome therapeutics market in 2021. Many of the drugs used to treat endogenous Cushing’s syndrome are specialized medications that may not be available in retail pharmacies. Hospital pharmacies are better equipped to stock and dispense these medications, making them an essential part of the treatment process. Hospital pharmacies work closely with healthcare providers to ensure that patients receive the most appropriate medications for their condition. This collaboration ensures that patients receive the right treatment at the right time, leading to better health outcomes, which boosts segmental growth. Endogenous Cushing’s syndrome is a complex condition that requires specialized care, and patients are usually treated in hospitals or specialized medical centers. Hospital pharmacies play a crucial role in ensuring that the right medications are available for patients.
Endogenous Cushing’s Syndrome Therapeutics Market by Region
Geographically, the global endogenous Cushing’s syndrome therapeutics market has been segmented into North America, Europe, Asia Pacific, and the rest of the world.
The North America market accounted for a significant revenue share in 2021. North America has a relatively high prevalence of endogenous Cushing’s syndrome, which is driving the demand for therapeutics in the region. According to the National Organization for Rare Disorders, the incidence rate of endogenous Cushing’s syndrome is approximately 13 per million people annually in the United States. North America has a well-developed healthcare infrastructure, including advanced hospitals and research centers, which supports the development and adoption of new and innovative therapeutics, which is boosting regional growth. A growing awareness of endogenous Cushing’s syndrome among healthcare professionals and the general population is leading to increased diagnosis of the condition and demand for therapeutics. North America is home to some of the world’s largest pharmaceutical companies, which are actively investing in the research and development of new therapeutics for endogenous Cushing’s syndrome. Government initiatives and funding for research and development of new therapeutics for endogenous Cushing’s syndrome are also driving market revenue growth in North America.
Endogenous Cushing’s Syndrome Therapeutics Market Competitive Landscape
The prominent players operating in the global endogenous Cushing’s syndrome therapeutics market are:
Endogenous Cushing’s Syndrome Therapeutics Market Strategic Developments
The endogenous Cushing’s syndrome therapeutics market was valued at US$ 97.12 million in 2021.
Endogenous Cushing’s syndrome is a medical condition caused by the overproduction of cortisol hormone by the adrenal glands. Cortisol is a hormone that regulates various bodily functions, including blood pressure, immune response, and metabolism. Endogenous Cushing’s syndrome can result from various causes, including a tumor in the pituitary gland or adrenal gland or from an overproduction of adrenocorticotropic hormone (ACTH) by the pituitary gland.
AbbVie Inc., AstraZeneca Plc, Pfizer Inc., GlaxoSmithKline Plc, and Merck & Co. Inc. are among the top market players.
The adrenal steroid inhibitors segment dominates the global endogenous Cushing’s syndrome therapeutics market.
North America accounts for the largest market share in terms of revenue. Asia Pacific is expected to register the fastest revenue CAGR during the forecast period.
*Insights on financial performance are subject to the availability of information in the public domain